NEW YORK — SphingoTec has signed a distribution agreement for its Nexus IB10 fully automated rapid immunoassay point-of-care instrument and related tests in India with Rivaara Labs, the companies said on Thursday.
Under the terms of the multiyear deal, Mumbai-based Rivaara will have the exclusive right to market the Nexus IB10 analyzer and tests in the Indian subcontinent. Included in the arrangement are tests for biomarkers including proenkephalin for the assessment of kidney function, bioactive adrenomedullin for assessing endothelial function, and dipeptidyl peptidase 3 for assessing cardiac depression.
Financial and other terms were not disclosed.
"This distribution agreement is an important step in making our near-patient diagnostics globally available," SphingoTec CFO and Managing Director Angelo Moesslang said in a statement.
In late 2020, Hennigsdorf, Germany-based SphingoTec struck a distribution deal for the Nexus IB10 and tests in the UK and Ireland with BHR Pharmaceuticals.